Abstract Context Glucagon-like peptide-1 receptor agonists (GLP1-RA) have potent glucose-lowering and weight loss benefits, but their effects on bone remain unclear. Objective To investigate changes in bone mineral density (BMD) in patients using semaglutide (SEM) and tirzepatide (TIR), a dual agonist of GLP-1/glucose dependent insulinotropic polypeptide. Methods Single-center retrospective study. Adult patients using SEM/TIR for ≥6 months with DXA scans before initiation and at least 6 months after were matched by age, sex, BMI, and diabetes mellitus (DM) to non-users with at least two DXA scans over the same period. The primary outcome was percentage change in total hip (TH) BMD. Results We included 255 patients using SEM or TIR in the GLP-1 RA group (92% female, mean age 64±9 years, BMI 31.0±5.6 kg/m²) and 255 controls. After a median follow-up of 17 months, the GLP-1 RA group achieved median 5% weight loss. Both groups had significant declines in BMD at TH and FN, with similar magnitude between groups. In the GLP-1RA group, weight loss was directly associated with bone loss at the TH and FN (r=0.32 for TH, r=0.17 for FN, both p0.01). Among patients without DM, greater TH bone loss was noted in GLP-1 RA group compared to controls (-1% vs -0.6%, p=0.04), whereas TH bone loss was similar between groups among patients with DM. Conclusion SEM/TIR use was associated with greater annualized TH bone loss in patients without DM, whereas TH bone loss was comparable between GLP-1 RA and controls in patients with DM. These findings suggest GLP-1 RA’s effects on bone may differ by DM status, with weight loss driving bone loss in patients without DM.
Liu et al. (Fri,) studied this question.